These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39089309)

  • 41. Experimental design and methods for school-based randomized trials. Experience from the Hutchinson Smoking Prevention Project (HSPP).
    Peterson AV; Mann SL; Kealey KA; Marek PM
    Control Clin Trials; 2000 Apr; 21(2):144-65. PubMed ID: 10715512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PPI in the PLEASANT trial: involving children with asthma and their parents in designing an intervention for a randomised controlled trial based within primary care.
    Boote J; Julious S; Horspool M; Elphick H; Smithson WH; Norman P
    Prim Health Care Res Dev; 2016 Nov; 17(6):536-548. PubMed ID: 26856306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials.
    Feliu-Soler A; Cebolla A; McCracken LM; D'Amico F; Knapp M; López-Montoyo A; García-Campayo J; Soler J; Baños RM; Pérez-Aranda A; Andrés-Rodriguez L; Rubio-Valera M; Luciano JV
    Behav Ther; 2018 Jan; 49(1):124-147. PubMed ID: 29405918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Epistemological Weight of Randomized-Controlled Trials Depends on Their Results.
    Flanagan RF; Dammann O
    Perspect Biol Med; 2018; 61(2):157-173. PubMed ID: 30146516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methodological challenges in online trials.
    Murray E; Khadjesari Z; White IR; Kalaitzaki E; Godfrey C; McCambridge J; Thompson SG; Wallace P
    J Med Internet Res; 2009 Apr; 11(2):e9. PubMed ID: 19403465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. When to randomize, or 'Evidence-based medicine needs medicine-based evidence'.
    Concato J
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():6-12. PubMed ID: 22552974
    [No Abstract]   [Full Text] [Related]  

  • 48. Measuring costs and financial benefits in randomized controlled trials.
    Bulpitt CJ; Fletcher AE
    Am Heart J; 1990 Mar; 119(3 Pt 2):766-70; discussion 770-1. PubMed ID: 2106770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficient use of endpoints in clinical trials: a clinical perspective.
    Terrin ML
    Stat Med; 1990; 9(1-2):155-60. PubMed ID: 2111931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Rosenheck RA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
    [No Abstract]   [Full Text] [Related]  

  • 51. Are systematic reviews more cost-effective than randomised trials?
    Glasziou P; Djulbegovic B; Burls A
    Lancet; 2006 Jun; 367(9528):2057-8. PubMed ID: 16798380
    [No Abstract]   [Full Text] [Related]  

  • 52. [Limits in health services research].
    Röllig C
    Urologe A; 2011 Jun; 50(6):697-701. PubMed ID: 21656095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Designing a cost-effective clinical trial.
    Hornberger JC; Brown BW; Halpern J
    Stat Med; 1995 Oct; 14(20):2249-59. PubMed ID: 8552901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From efficacy to cost-effectiveness.
    Kernick DP
    Lancet; 1997 Dec; 350(9093):1781. PubMed ID: 9413494
    [No Abstract]   [Full Text] [Related]  

  • 55. From efficacy to cost-effectiveness.
    Thompson S; Barber J
    Lancet; 1997 Dec; 350(9093):1781-2. PubMed ID: 9413495
    [No Abstract]   [Full Text] [Related]  

  • 56. On cost effectiveness and sample size in clinical trials.
    Hart AA; Dijkgraaf MG
    Pharmacoeconomics; 2004; 22(10):685-8, author reply 688-9. PubMed ID: 15244493
    [No Abstract]   [Full Text] [Related]  

  • 57. Trial-based clinical and economic analyses: the unhelpful quest for conformity.
    Whitehurst DG; Bryan S
    Trials; 2013 Dec; 14():421. PubMed ID: 24308301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.
    Manca A; Sculpher MJ; Goeree R
    Pharmacoeconomics; 2010; 28(12):1079-96. PubMed ID: 21080734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians' Health Study.
    Hennekens CH; Buring JE
    Control Clin Trials; 1989 Dec; 10(4 Suppl):142S-150S. PubMed ID: 2605963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, analysis, and presentation of crossover trials.
    Mills EJ; Chan AW; Wu P; Vail A; Guyatt GH; Altman DG
    Trials; 2009 Apr; 10():27. PubMed ID: 19405975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.